Rolfo, Christian http://orcid.org/0000-0002-5109-0267
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Hong, David
McCoach, Caroline
Dowlati, Afshin
Lin, Jessica J.
Russo, Alessandro
Schram, Alison M.
Liu, Stephen V.
Nieva, Jorge J.
Nguyen, Timmy
Eshaghian, Shahrooz
Morse, Michael
Gettinger, Scott
Mobayed, Mohammad
Goldberg, Sarah
Araujo-Mino, Emilio
Vidula, Neelima
Bardia, Aditya
Subramanian, Janakiraman
Sashital, Deepa
Stinchcombe, Thomas
Kiedrowski, Lesli
Price, Kristin
Gandara, David R.
Article History
Received: 25 April 2021
Revised: 10 August 2021
Accepted: 20 August 2021
First Online: 3 September 2021
Ethics approval and consent to participate
: This research was conducted in accordance with the Declaration of Helsinki. Institutional Review Board approval (Advarra IRB Pro00034566/CR00218935) waived the need for individual informed consent for use of deidentified aggregate data for research purposes.
: Not applicable.
: Dr. Rolfo reports grants for Lung Cancer Research Foundation-Pfizer Grant 2019 NHI U54 grant (Project co-leader); He has received personal fees for attending advisory board with Inivata, ArcherDx, EMD Serono, BMS, Novartis, Boston Pharmaceuticals, Pfizer, Mirati, and Eisai; fee for speaking bureau: MSD, Astra Zeneca, Roche, and GuardantHealth; Participation in Safety Monitoring Board for EMD Serono Non-financial conflict included research collaboration: GuardantHealth. Dr. Drilon reports Honoraria/Advisory Boards from Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX; Associated Research to Institution from Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar; Royalties from Wolters Kluwer; Other from Merck, Puma, Merus, Boehringer Ingelheim. Dr. Russo reports consultancy for Astra Zeneca, MSD, and Novartis outside the submitted work. Dr. Stinchcombe reports personal fees from Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, Regeneron, non-financial support from Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, Regeneron, outside the submitted work. Dr. Vidula reports institutional research funding from Radius, Merck, Daehwa, Pfizer (and travel), and Novartis; advisory board from AbbVie; Dr. Price is an employee and stock holder of Guardant Health.